Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;69(6):2592-2598.
doi: 10.1002/bab.2308. Epub 2022 Jan 13.

Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2

Maryam Ranjbar  1 , Marzieh Asadi  1 , Marjan Nourigorji  2 , Bahador Sarkari  3   4 , Zohreh Mostafavi-Pour  5   6 , Kamiar Zomorodian  3   4 , Zahra Shabaninejad  7   8 , Mortaza Taheri-Anganeh  1 , Amir Maleksabet  9 , Mohsen Moghadami  10   11 , Amir Savardashtaki  1   12
Affiliations

Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2

Maryam Ranjbar et al. Biotechnol Appl Biochem. 2022 Dec.

Abstract

Coronavirus 2019 (COVID-19) is a global concern for public health. Thus, early and accurate diagnosis is a critical step in management of this infectious disease. Currently, RT-PCR is routine diagnosis test for COVID-19, but it has some limitations and false negative results. enzyme-linked immunosorbent assay (ELISA) against SARS-CoV-2 antigens seems to be an appropriate approach for serodiagnosis of COVID-19. In the current study, an ELISA system, using a recombinant nucleocapsid (N) protein, was developed for the detection of IgM and IgG antibodies to SARS-CoV-2. The related protein was expressed, purified, and used in an ELISA system. Sera samples (67) for COVID-19 patients, as well as sera samples from healthy volunteers (112), along with sera samples from non-COVID-19 patients were examined by the ELISA system. The expression and purity of the recombinant N protein were approved by SDS-PAGE and Western blotting. The sensitivity of ELISA system was 91.04 and 92.53% for the detection of IgG and IgM antibodies, respectively. Moreover, the specificity of the developed ELISA system for IgG and IgM were 98.21 and 97.32%, respectively. Our developed ELISA system showed satisfactory sensitivity and specificity for the detection of antiSARS-CoV-2 IgM and IgG antibodies and could be used as a complementary approach for proper diagnosis of COVID-19.

Keywords: COVID-19; ELISA; SARS-CoV-2; antibodies; nucleocapsid; recombinant.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) SDS‐PAGE analysis of the recombinant N protein expression and purification. Lane 1: molecular weight marker; Lanes 2, 3, 4, 5, 6, and 7 noninduced, induced, prewash, wash 1, wash 2, and elution with His‐tag, respectively. (B) The membrane was incubated with anti‐His antibody to verify the identity of the N recombinant protein. Lane 1: size maker, Lane 2: protein incubated with anti‐His tag. (C) The membrane was cut into two strips and was separately incubated with sera of confirmed SARS‐CoV‐2 patients (Lane 3) and sera of healthy volunteers (Lane 1)
See this image and copyright information in PMC

References

    1. Taheri‐Anganeh M, Khatami SH, Jamali Z, Savardashtaki A, Ghasemi Y, Mostafavi‐Pour Z. In silico analysis of suitable signal peptides for secretion of a recombinant alcohol dehydrogenase with a key role in atorvastatin enzymatic synthesis. Mol Biol Res Commun. 2019;8(1):17. - PMC - PubMed
    1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet North Am Ed. 2020;395(10224):565‐74. - PMC - PubMed
    1. Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person‐to‐person transmission of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in the USA. Lancet.. 2020. - PMC - PubMed
    1. Gkiouras K, Nigdelis MP, Grammatikopoulou MG, Goulis DG. Tracing open data in emergencies: The case of the COVID‐19 pandemic. Eur J Clin Invest. 2020;50(9):e13323. - PMC - PubMed
    1. Zhou L, Zhang M, Wang J, Gao J. Sars‐Cov‐2: Underestimated damage to nervous system. Travel Med Infect Dis. 2020;101642 (10.1016). - PMC - PubMed